Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow bioAffinity Technologies, Inc.

Get SEC filing alerts via email and in your feed for bioAffinity Technologies, Inc.

BIAF BIAFW

bioAffinity Technologies, Inc.

About bioAffinity Technologies, Inc.

bioAffinity Technologies develops noninvasive diagnostic tests for early lung cancer detection using flow cytometry and AI-driven analysis of sputum samples. Its flagship product, CyPath Lung, aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and support timely treatment. The company also explores therapeutic discoveries and operates a clinical laboratory, serving high-risk populations and healthcare providers worldwide in the growing cancer diagnostics market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from bioAffinity Technologies, Inc.

1
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports $1.35 Million Revenue and $3.63 Million Net Loss for Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports $6.2 Million Revenue for Fiscal Year 2025, Faces Increased Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports 38% Revenue Decline and Increased Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports 47% Revenue Decline and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports $1.85 Million Revenue and $2.66 Million Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports 270% Revenue Growth to $9.4 Million in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
bioAffinity Technologies, Inc. bioAffinity Technologies Reports Significant Revenue Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments